<![CDATA[ODC Life Sciences]]>https://www.orphandc.com/blogRSS for NodeWed, 03 Jun 2026 13:22:33 GMT<![CDATA[New Clinical Research Law in Brazil: Innovation, Agility, and Ethics]]>https://www.orphandc.com/post/new-clinical-research-law-in-brazil-innovation-agility-and-ethics6671ac4e9e1700ad68fdbb80Tue, 18 Jun 2024 15:54:06 GMTfernandorangel0<![CDATA[Celebrating Nurse's Day: A Tribute from ODC Life Sciences]]>https://www.orphandc.com/post/celebrating-nurse-s-day-a-tribute-from-odc-life-sciences6671aa83edddd541b15d8523Tue, 18 Jun 2024 15:47:33 GMTfernandorangel0<![CDATA[AACR Review - Observed Trends in Cancer Research]]>https://www.orphandc.com/post/aacr-review-observed-trends-in-cancer-research664f46a59535c0de4306175dThu, 23 May 2024 13:49:14 GMTfernandorangel0<![CDATA[Women in Science ]]>https://www.orphandc.com/post/women-in-science664f4329433b7b96ca76a116Thu, 23 May 2024 13:36:18 GMTfernandorangel0<![CDATA[ACCESSIBLE PATIENT COMMUNITIES: A TWO-YEAR EVOLUTION IN LATAM’S RARE DISEASE LANDSCAPE, FOCUS IN BRAZIL, MEXICO, ARGENTINA, AND COLOMBIA]]>https://www.orphandc.com/post/accessible-patient-communities-a-two-year-evolution-in-latam-s-rare-disease-landscape-focus-in-bra65eb2c1289ca9d0f81248a06Fri, 08 Mar 2024 15:29:41 GMTfernandorangel0<![CDATA[FDA REQUIREMENTS FOR DIVERSITY INCLINICAL TRIALS: LATAM OPPORTUNITY]]>https://www.orphandc.com/post/fdarequirementsfor-diversity-inclinical-trials-latamopportunity65eb26af92125bc8f2f1a10fFri, 08 Mar 2024 14:56:14 GMTfernandorangel0<![CDATA[BRAZIL AIMS FOR TOP 10 SPOT IN CLINICAL RESEARCH]]>https://www.orphandc.com/post/brazil-aims-for-top-10-spot-inclinical-research65eb18886fe74374128a8e4bFri, 08 Mar 2024 14:18:16 GMTfernandorangel0